My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

2.870 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.870
Bid (Size) 2.880 (1)
Ask (Size) 2.960 (4)
Prev. Close 2.870
Today's Range 2.870 - 2.870
52wk Range 1.050 - 3.400
Shares Outstanding 64,465,037
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Driving the Market Sentiment Around Taysha Gene Therapies?
 
Via Benzinga
Is Taysha Gene Therapies Gaining or Losing Market Support?
 
Via Benzinga

Performance

YTD
+55.1%
+55.1%
1 Month
-1.7%
-1.7%
3 Month
+15.3%
+15.3%
6 Month
+72.9%
+72.9%
1 Year
+41.4%
+41.4%

More News

Read More
A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts
Via Benzinga
What's Next: Taysha Gene Therapies's Earnings Preview
Via Benzinga
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock
Via Benzinga
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data
Via Stocktwits
Where Taysha Gene Therapies Stands With Analysts
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Assessing Taysha Gene Therapies: Insights From 8 Financial Analysts
Via Benzinga
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts
Via Benzinga
Earnings Scheduled For August 12, 2025
Via Benzinga
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
Via Chartmill
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Via Benzinga
Top stock movements in today's session.
Via Chartmill
Earnings Scheduled For May 15, 2025
Via Benzinga
Monday's session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Via Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
Via Benzinga
Topics Stocks
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Frequently Asked Questions

Is Taysha Gene Therapies, Inc. - Common Stock publicly traded?
Yes, Taysha Gene Therapies, Inc. - Common Stock is publicly traded.
What exchange does Taysha Gene Therapies, Inc. - Common Stock trade on?
Taysha Gene Therapies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Taysha Gene Therapies, Inc. - Common Stock?
The ticker symbol for Taysha Gene Therapies, Inc. - Common Stock is TSHA on the Nasdaq Stock Market
What is the current price of Taysha Gene Therapies, Inc. - Common Stock?
The current price of Taysha Gene Therapies, Inc. - Common Stock is 2.870
When was Taysha Gene Therapies, Inc. - Common Stock last traded?
The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 09/22/25 04:00 PM ET
What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?
The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 185.01M
How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?
Taysha Gene Therapies, Inc. - Common Stock has 185M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.